Near infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy

Journal: Nature Communications

Published: 2018-07-04

DOI: 10.1038/s41467-018-04763-y

Affiliations: 13

Authors: 7

Go to article

Research Highlight

Tiny attackers for treating tumours



Biocompatible and biodegradable nanoparticles that carry drugs directly to cancer cells, and can be simultaneously imaged, could reduce the side effects of chemotherapy.

Oesophageal cancer is the sixth most deadly cancer in the world. Existing drugs, such as epirubicin, can have harmful side effects when they end up in the wrong cells.

A team that included researchers from Northwestern Polytechnical University in China has made a naturally fluorescent nanoparticle from short amino acids chains, which can be broken down safely in the body.

They tuned the nanoparticle to target oesophageal cancer cells and used infrared imaging to watch it making a beeline for a tumour. The researchers then loaded their nanoparticle with epirubicin and injected it into mice with oesophageal cancer, where it slowed tumour growth and had fewer side effects than when epirubicin was used alone.

Such precision drug delivery and imaging by biodegradable nanoparticles could improve the outcomes of chemotherapy for oesophageal cancer.

Supported content

  1. Nature Communications 9, 2605 (2018). doi: 10.1038/s41467-018-04763-y
Institutions Share
The University of Texas at Arlington (UTA), United States of America (USA) 0.32
Northwestern Polytechnical University (NPU), China 0.14
The Ohio State University (OSU), United States of America (USA) 0.12
Ohio State University Wexner Medical Center (OSUWMC), United States of America (USA) 0.08
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA) 0.07
VA North Texas Health Care System, United States of America (USA) 0.07
Tongji University, China 0.06
Sun Yat-sen University Cancer Center (SYSUCC), SYSU, China 0.04
Collaborative Innovation Center for Cancer Medicine, China 0.04
Xinxiang Medical University (XXMU), China 0.04
OSU Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), United States of America (USA) 0.03